DECISION-MAKING AND PROBLEM SOLVING IN COMPLEX PCI: INTERACTIVE CASE-BASED LEARNING (I)

Prof Javier Escaned is Head of Interventional Cardiology Section at Hospital Clinico San Carlos (Madrid, Spain). He trained as a cardiologist the United Kingdom before moving to the Thoraxcenter / Rotterdam (The Netherlands), where he obtained his PhD degree in 1994. With over 30 years of experience as interventionalist, he regularly serves as live case operator and educationalist in global events. He is author of over 500 PubMed indexed scientific articles (h-index 74) on topics that include complex PCI in multivessel disease, left main and chronic total occlusions. His track record in coronary physiology includes being investigator on pivotal FFR trials like DEFER (1998), collaborator with Justin Davies in the validation and clinical implementation of iFR (since 2010), and developer of new methods for the assessment of microvascular and non-obstructive coronary disease. Editorial work includes two large textbooks (“Coronary Stenosis. Imaging, Structure and Physiology” and “Physiological Assessment of Coronary Stenoses and the Microcirculation) and editorial board positions in scientific journals. Board positions in scientific societies include EuroPCR, EAPCI, EuroCTO and the ESC Working Group of Coronary Pathophysiology and Microcirculation. Additional interest incllude music and phylosophy. He is a recipient of the ESC Silver Medal and the 2022 ESC Andreas Gruentzig Award.

Dr Justin Davies is founder and CEO of Wondr Medical, inventor of iFR, and clinical academic and consultant interventional cardiologist at the National Heart and Lung Institute, Imperial College London.

Dr Richard A. Shlofmitz, MD, FACC is the Chairman of Cardiology at St. Francis Hospital, The Heart Center®, in Roslyn, New York. A pioneer in interventional cardiology, Dr. Shlofmitz has worked to advance the field, with a focus on optimizing outcomes with the development of Precision PCI. He is a founding co-director of the annual Intravascular Imaging and Coronary Physiology Workshop. Performing over 1,000 coronary interventions annually, he has one of the largest volumes of experience in PCI. He has the most clinical experience with orbital atherectomy and OCT world-wide. His clinical research interests focus on optimizing coronary interventions and he serves on multiple scientific advisory boards and clinical trial steering committees to further this mission. Dr Shlofmitz has been one of the largest enrollers for multiple clinical trials, including TWILIGHT, ILUMIEN III, and Onyx, with more than 75 publications in peer-reviewed journals and was first to perform coronary intravascular lithotripsy (IVL) in North America as part of the DISRUPT CAD III trial.

Dr Roberto Garbo is an Interventional Cardiologist in Maria Pia Hospital GVM Care & Research, Turin, Italy. He is a Director of CTO and Complex PCI program, Board member of EuroCTO Club since 2017 and IVUS guided CTO expert in both antegrade and retrograde approach. Dr Garbo is a Director of Turin CTO&CHIp Live course.

Ziad Ali is the Director of the DeMatteis Cardiovascular Institute, Director of Investigational Interventional Cardiology, and Director of Cardio-nephrology at St Francis Hospital & Heart Center in New York. He is also Director of the Angiographic Core Laboratory at Cardiovascular Research Foundation and Associate Professor of Medicine at Columbia University Medical Center. His clinical research interests focus on the use of intravascular imaging and physiology technologies such as optical coherence tomography, intravascular ultrasound, and flow wire assessment to optimize coronary interventions, for which he has served as a Global principal investigator on a number of trials. Dr. Ali is also a recognized innovator, playing an integral role in the development of the Resting Full-Cycle Ratio (RFR) and Shockwave intravascular lithotripsy. Clinically Dr. Ali developed pioneering techniques to perform vascular interventions without contrast administration, including IVUS-guided zero-contrast PCI and OCT using saline flush media, protecting patients with advanced kidney disease from acute kidney injury and the need for dialysis.